# Predict Risks for Safer Therapies
Cardiac toxicity remains one of the primary causes of late-stage drug failures, making early detection essential in drug development. VitroVo provides precise, reliable, and cost-effective cardiac toxicity profiling solutions using advanced ultra high-density microelectrode array (UHD-MEA) technology. Our assays empower you to predict cardiac risks with unparalleled accuracy, ensuring safer therapeutic outcomes.
Assessing the cardiac safety of drug candidates early in development offers:
Regulatory Compliance: Meet industry safety standards and regulatory requirements for cardiac toxicity testing (e.g., ICH S7B and CiPA guidelines).
Improved Clinical Success Rates: Identify proarrhythmic risks and QT prolongation early to prevent costly trial failures.
Comprehensive Safety Profiling: Understand how compounds impact electrophysiological parameters critical for cardiac function.
Reduced Use of Animal Testing: Utilize human-relevant in-vitro models to gain predictive insights efficiently.
Capture electrophysiological activity with unparalleled resolution with a new set of parameters, including beat area size, beat propagation velocity, number of beat origin point.
Record at the single-cell level to gain deeper insights into cardiac electrophysiology.
Apply advanced data processing techniques, such as machine learning, to detect subtle, compound-induced cardiotoxic effects.
Perform multivariate analyses (e.g., PCA, UMAP) to uncover hidden patterns linked to cardiac toxicity.
We use human iPSC-derived cardiomyocytes for compound evaluation on MEA. Only wells and plates that meet stringent criteria for key functional parameters are selected for compound administration.
Two Decades of Expertise: Extensive experience in MEA-based cardiac safety assessments.
Human-Relevant Models: Reduce reliance on animal studies with predictive in-vitro systems.
Cost-Effective and Scalable Solutions: Perform high-throughput screening to evaluate multiple conditions in parallel, saving time and resources.
Multimodal Data Integration: Combine electrophysiology with molecular and imaging data for a holistic safety profile.
VitroVo’s state-of-the-art cardiac toxicity profiling services provide the insights you need to predict, prevent, and mitigate cardiac risks in drug development. With cutting-edge technologies and human-relevant models, we deliver confidence in your compound’s safety profile.
Ready to optimize your cardiac safety strategy? Reach out to our team today to explore how VitroVo can accelerate your research and ensure safer drug development outcomes.
See assay examples below to find out how VitroVo can advance your cardiac toxicity research
No assay found for cardiac toxicity. Please check back for future updates.